Abionyx
A French biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones.
In January 2023, Abionyx reported that the pilot Phase IIa trial of CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) met its primary objective.
Latest Abionyx News & Features
10 January 2024
16 January 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze